Skip to main content
letter
. 2020 May 6;55(11):2180–2184. doi: 10.1038/s41409-020-0931-4

Table 1.

Clinical characteristics, treatments and outcomes of patients with hematological malignancies and SARS-CoV-2 infection.

Patient No Age Sex BMI Hemalogical disease Hematological status Hematological treatment Ongoing corticosteroids Number of treatment lines Previous transplant Comorbidities Time between onset of symptoms and diagnosis (days) Radiologic diagnosis ARDS Invasive mechanical ventilation COVID-19 management Follow-up since first symptoms (days) Survival status
1 65 M 28.7 Myeloma Complete remission Ongoing isatuximab + DXM maintenance Yes 2 Autologous HBP 3 Positive CT Yes Yes Best supportive care 17 Dead
2 73 F 30.2 Myeloma Diagnosis None No 0 No Diabetes, HBP, stroke, obesity 4 Positive X-ray Yes Yes Best supportive care 13 Dead
3 65 M 24.3 Myeloma Complete remission Ongoing lenalidomide maintenance No 1 Autologous HBP 4 ND No No HCQ/AZT + Tociluzumab 40 Alive
4 61 M 41.5 Lymphoma (DLBCL) Complete remission None, 3 months post CAR T-cell No 4 Autologous and allogeneic Diabetes, HBP, obesity 7 Positive CT Yes Yes Best supportive care 38 Alive
5 61 F 31.6 Myeloma Partial remission Ongoing carfilzomib + lenalidomide + DXM Yes 6 Autologous Diabetes, HBP, stroke, obesity 7 Positive CT No No Lopinavir-ritonavir 34 Alive
6 45 M 45.8 PNH Partial remission Ongoing eculizumab No 1 No Obesity 4 Positive CT Yes Yes Best supportive care 32 Alive
7 40 F 26.7 ALL Complete remission None, 9 months post allo-HSCT No 1 Allogeneic No 0 Positive CT Yes Yes Best supportive care 23 Alive
8 78 M 26.3 MDS Progressive disease Best supportive care Yes 0 No Glioma, stroke 1 Positive X-ray Yes No Tociluzumab + corticosteroids 10 Dead
9 79 M 37.8 Lymphoma (hairy cell) Complete remission None, 12 years post Cladribine No 2 No HBP, obesity, CKD, MDS, MGUS 2 Positive X-ray No No Lopinavir-ritonavir 26 Alive
10 62 F 24.2 LGL leukemia Complete remission None, 18 months post cyclophosphamide No 1 No No 1 Positive CT No No Best supportive care 32 Alive
11 75 M 28.7 MDS Progressive disease Best supportive care No 0 No Diabetes, HBP 7 Positive CT Yes No Best supportive care 27 Dead
12 81 M 21.3 Myeloma Partial remission Ongoing lenalidomide + DXM Yes 1 No HBP 3 Positive CT Yes No Best supportive care 10 Dead
13 81 M 30.1 Lymphoma (Marginal zone) Progressive disease None, 14 months post rituximab + bendamustine No 1 No Diabetes, HBP, stroke, obesity, COPD 0 ND No No Best supportive care 35 Alive
14 63 M 25.0 Lymphoma (hairy cell) Complete remission None, 5 years post rituximab No 2 No HBP 5 ND No No Best supportive care 32 Alive
15 92 M 20.0 Myeloma Progressive disease Ongoing cyclophosphamide + prednisone Yes 3 No HBP 14 Positive X-ray Yes No Best supportive care 14 Dead
16 89 M 23.6 Myeloma Stable disease Ongoing lenalidomide + DXM Yes 2 No CKD 6 Positive CT Yes No Best supportive care 21 Dead
17 61 M 23.9 Myeloma Complete remission Ongoing bortezomib maintenance No 2 Autologous Cardiomyopathy 12 Positive X-ray No No Best supportive care 29 Alive
18 86 M 22.3 CLL Stable disease Wait and watch No 0 No HBP, stroke, CKD 10 Positive X-ray Yes No Lopinavir-ritonavir + corticosteroids 17 Dead
19 68 F 24.4 Myeloma Partial remission Ongoing daratumumab + lenalidomide + DXM Yes 2 No Diabetes, HBP 1 Positive CT Yes Yes Lopinavir-ritonavir + corticosteroids + tociluzumab 17 Alive
20 72 F 31.5 Myeloma Partial remission Ongoing daratumumab + lenalidomide + DXM Yes 1 No HBP, obesity 0 Positive CT No No Best supportive care 20 Alive
21 76 M 19.3 MDS Progressive disease Best supportive care No 1 No CKD, COPD 3 Positive CT No No Best supportive care 20 Alive
22 97 F 17.2 MDS Progressive disease Best supportive care No 1 No Pancreatic adenocarcinoma, CKD 2 ND Yes No Best supportive care 4 Dead
23 71 M 24.1 Lymphoma (DLBCL) Complete remission Ongoing rituximab maintenance No 2 Autologous HBP, stroke 22 Positive CT No No Anakinra 29 Alive
24 63 M 22.8 Lymphoma (Poppema) Complete remission Ongoing rituximab-CHOP Yes 1 No HBP 10 Positive X-ray No No Best supportive care 19 Alive
25 75 F 41.4 Waldenström macroglobulinemia Partial remission Ongoing rituximab + cyclophosphamide + DXM Yes 3 No HBP, obesity, epidermoid carcinoma of the anal canal 1 Positive CT No No Best supportive care 14 Alive

M male, F female, BMI body mass index (kg/m2), DLBLC diffuse large B-cell lymphoma, PNH paroxysmal nocturnal hemoglobinuria, ALL acute lymphoblastic leukemia, MDS myelodysplastic syndrome, LGL large granular lymphocyte, CLL chronic lymphoid leukemia, DXM dexamethasone, allo-HSCT allogeneic hematopoietic stem cell transplantation, HBP high blood pressure, CKD chronic kidney disease, MGUS monoclonal gammopathy of undertemined significance, COPD chronic obstructive pulmonary disease, CT computed tomography, HCQ hydroxychloroquine, AZT azithromycine.